Empyrean is using genetic engineering to treat severe neuropsychiatric and neurologic illnesses in a way that will revolutionize healthcare.
Empyrean Neuroscience has raised $22.0M in total funding. The most recent round was Series A. The last funding was announced in October 2022.
Empyrean Neuroscience's investors include Spore Partners.
Empyrean Neuroscience is headquartered in New York, United States.
Empyrean is using genetic engineering to treat severe neuropsychiatric and neurologic illnesses in a way that will revolutionize healthcare.
Empyrean Neuroscience is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Empyrean Neuroscience — Funding & Investors." VCBacked, October 18, 2022, https://www.vcbacked.co/company/empyrean-neuroscience. Accessed August 14, 2026.
VCBacked. (2022). Empyrean Neuroscience — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/empyrean-neuroscience
{{cite web |title=Empyrean Neuroscience — Funding & Investors |url=https://www.vcbacked.co/company/empyrean-neuroscience |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated